1. Hepatic Allograft Rejection: New Developments in Terminology, Diagnosis, Prevention, and Treatment 
RUSSELL H. WIESNER, M.D., JURGEN LUDWIG, M.D., RUUD A.F. KROM, M.D., Ph.D., J. EILEEN HAY, M.D., BART VAN HOEK, M.D. 
Mayo Clinic Proceedings 
Volume 68, Issue 1, Pages (January 1993)
DOI: /S (12)
Copyright © 1993 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Fig. 1
Incidence of cellular and ductopenic rejection among Mayo Clinic patients who underwent liver transplantation, stratified by various combinations of induction immunosuppression. ALG = antilymphocyte globulin; Aza = azathioprine; CyA = cyclosporine; Pred = prednisone.
Mayo Clinic Proceedings  , 69-79DOI: ( /S (12) )
Copyright © 1993 Mayo Foundation for Medical Education and Research Terms and Conditions

3. Fig. 2
Comparison of incidence and timing of rejection after liver transplantation when induction immunosuppression consisted of OKT3 versus triple-drug therapy with cyclosporine (CyA), prednisone (Pred), and azathioprine
(Aza). (From Cosimi and associates.38 By permission of the American Medical Association.)
Mayo Clinic Proceedings  , 69-79DOI: ( /S (12) )
Copyright © 1993 Mayo Foundation for Medical Education and Research Terms and Conditions

4. Fig. 3
Effects of FK-506 and cyclosporine on renal function in recipients of liver transplants.
Mayo Clinic Proceedings  , 69-79DOI: ( /S (12) )
Copyright © 1993 Mayo Foundation for Medical Education and Research Terms and Conditions

5. Fig. 4
Incidence of hypertension associated with FK-506 and cyclosporine therapy in recipients of liver transplants.
(Modified from Tzakis AG, Reyes J, Todo S, Green M, Ohya T, Jain A, et al. FK-506 versus cyclosporine in pediatric liver transplantation. Transplant Proc 1991; 23: By permission of Appleton & Lange.)
Mayo Clinic Proceedings  , 69-79DOI: ( /S (12) )
Copyright © 1993 Mayo Foundation for Medical Education and Research Terms and Conditions

6. Fig. 5
Incidence of corticosteroid-resistant and OKT3-resistant hepatic allograft rejection based on dose and route of corticosteroid therapy for initial episode of rejection. Groups 1 and 2 versus group 3, P<0.01. MP = methylprednisolone (intravenous administration); Pred = prednisone (oral administration).
Mayo Clinic Proceedings  , 69-79DOI: ( /S (12) )
Copyright © 1993 Mayo Foundation for Medical Education and Research Terms and Conditions